REG - Surgical Innovations - Trading Update

Surgical InnovationsAnnouncement

18/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0249Ma&default-theme=true

RNS Number : 0249M  Surgical Innovations Group PLC  18 December 2025

Surgical Innovations Group plc

("Surgical Innovations", the "Company", or the "Group")

 
Trading update

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and
distributor of innovative medical technology for minimally invasive surgery,
provides the following update on trading ahead of its year ended 31 December
2025.

 

Sales in the final quarter have been softer than anticipated due to a number
external factors including:

 

·    The global flu epidemic is impacting the Group across its key markets
in Europe, APAC and ROW and has led to a reduction in elective surgical
procedures.

·    This has been compounded by continued industrial action in the NHS
taking place in September and further strikes scheduled for next week,
contributing to additional delays in elective procedures and increased
seasonal pressure on NHS capacity.

·    Sales in December have also been adversely affected by a one-off
quality issue relating to key components supplied by an OEM partner, which
constrained our manufacturing of their product. The issues have been promptly
addressed and supply is resuming, with normal deliveries expected in early
2026.

 

As a result of these unanticipated market factors, the Company expects
revenues for the year to now be c. £11.5m with a commensurate impact on
profits. In addition, as part of its review of year-end inventory holdings,
the Board has taken the prudent decision to increase its provision held
against slow moving raw material stock.

 

Net debt as of 17 December 2025 was £0.4m and the Company continues to
closely monitor its working capital position.

 

The Board remains confident of the growing focus on environmental
sustainability driving organisations to adopt greener practices, with Surgical
Innovations well positioned to capitalise on offering a sustainable solution
with the Company's reposable™ technology aligning with this shift.

 

David Marsh, CEO of Surgical Innovations, said: "Whilst we are naturally
disappointed with the external market forces having a direct impact on the
Group's performance, we remain confident in our reposable™ technology and
the overall prospects of the Group going forward.  We look forward to
updating shareholders at our full year results."

 

 

For further information please contact:

 

 Surgical Innovations Group plc                                                www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                                              Tel: 0113 230 7597
 Brent Greetham, CFO

 Singer Capital Markets (Nominated Adviser & Broker)                                                     Tel: 020 7496 3000
 Alex Bond / Graham Hertrich

 Walbrook PR (Financial PR & Investor Relations)      Tel: 020 7933 8780 or si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Lianne Applegarth                                              Mob: 07980 541 893 / 07584 391 303

 

 

 

 

 

About Surgical Innovations Group plc

 

The Group specialises in the design, manufacture, sale and distribution of
innovative, high quality medical products, primarily for use in minimally
invasive surgery. Our product and business development is guided and supported
by a key group of nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical
instruments and retraction devices which are sold directly in the UK home
market through our subsidiary, Elemental Healthcare, and exported widely
through a global network of trusted distribution partners. Many of our
products in this field are based on a "resposable" concept, in which the
products are part reusable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive against
fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist
products employed in laparoscopy, bariatric and metabolic surgery, hernia
repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM
partners and have also collaborated with a major UK industrial partner to
provide precision engineering solutions to complex problems outside the
medical arena.

 

We aim for our brands to be recognised and respected by healthcare
professionals in all major geographical markets in which we operate and
provide by development, partnership or acquisition a broad portfolio of cost
effective, procedure specific surgical instruments and implantable devices
that offer reliable solutions to genuine clinical needs, the Company's
Reposable portfolio enables healthcare providers to reduce both plastic waste
and their CO2 footprint as they strive for net zero.

 

 

Further information

Further details of the Group's businesses and products are available on the
following websites:

 

www.sigroupplc.com (http://www.sigroupplc.com)

www.surginno.com (http://www.surginno.com/)

www.elementalhealthcare.co.uk (http://www.elementalhealthcare.co.uk)

 

 

To receive regular updates by email, please contact si@walbrookpr.com
(mailto:si@walbrookpr.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFFFVIFFLDLIE



            Copyright 2019 Regulatory News Service, all rights reserved